- Home
- SCNX vs CRIS Comparison
SCNX vs CRIS Comparison
Compare SCNX & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCNX
- CRIS
- Stock Information
- Founded
- SCNX 2010
- CRIS 2000
- Country
- SCNX United States
- CRIS United States
- Employees
- SCNX N/A
- CRIS N/A
- Industry
- SCNX Other Pharmaceuticals
- CRIS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SCNX Health Care
- CRIS Health Care
- Exchange
- SCNX Nasdaq
- CRIS Nasdaq
- Market Cap
- SCNX 31.5M
- CRIS 18.6M
- IPO Year
- SCNX 2020
- CRIS 2000
- Fundamental
- Price
- SCNX $0.72
- CRIS $1.30
- Analyst Decision
- SCNX
- CRIS Strong Buy
- Analyst Count
- SCNX 0
- CRIS 2
- Target Price
- SCNX N/A
- CRIS $16.50
- AVG Volume (30 Days)
- SCNX 64.5M
- CRIS 80.1K
- Earning Date
- SCNX 11-12-2025
- CRIS 11-06-2025
- Dividend Yield
- SCNX N/A
- CRIS N/A
- EPS Growth
- SCNX N/A
- CRIS N/A
- EPS
- SCNX N/A
- CRIS N/A
- Revenue
- SCNX $128,202.00
- CRIS $11,650,000.00
- Revenue This Year
- SCNX N/A
- CRIS $2.72
- Revenue Next Year
- SCNX N/A
- CRIS $8.27
- P/E Ratio
- SCNX N/A
- CRIS N/A
- Revenue Growth
- SCNX N/A
- CRIS 13.56
- 52 Week Low
- SCNX $0.46
- CRIS $1.02
- 52 Week High
- SCNX $8.72
- CRIS $4.70
- Technical
- Relative Strength Index (RSI)
- SCNX 46.40
- CRIS 26.64
- Support Level
- SCNX $0.69
- CRIS $1.46
- Resistance Level
- SCNX $1.11
- CRIS $1.49
- Average True Range (ATR)
- SCNX 0.31
- CRIS 0.09
- MACD
- SCNX -0.03
- CRIS -0.02
- Stochastic Oscillator
- SCNX 12.58
- CRIS 19.15
About SCNX Scienture Holdings Inc. Common Stock
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.